Home Wellness Insights

21Jul

Semaglutide Statistics 2026: Ozempic & Wegovy Data, Clinical Outcomes & Market Trends | GoalBMI

Semaglutide Statistics 2026: Ozempic & Wegovy Data, Clinical Outcomes & Market Trends | GoalBMI Wellness

📊 Statistics Report — Updated July 2026

Semaglutide Statistics 2026: Ozempic & Wegovy Data, Clinical Outcomes & Market Trends

The most comprehensive semaglutide statistics resource for 2026. Covers Ozempic and Wegovy sales data, STEP trial weight loss outcomes, SELECT cardiovascular results, the oral Wegovy launch, who is using semaglutide in America, and what the latest 2026 research shows.

📅 Last Updated: July 2026 ⏱ 12 min read ✔ Physician Reviewed 📚 13 Cited Sources

$0B

Semaglutide franchise projected 2026 global sales

Heally.com, June 2026

Average weight loss — STEP-1 trial at 68 weeks

NEJM STEP-1, 2021

Reduction in cardiovascular events — SELECT trial

NEJM SELECT, 2023

Oral Wegovy prescriptions in first 4 months after launch

Heally.com, June 2026

Semaglutide — sold as Ozempic, Wegovy, and Rybelsus — has become the most recognized prescription medication in the world. From its origins as a diabetes drug to its current role as a frontline weight loss treatment with proven cardiovascular benefits, semaglutide’s clinical profile and commercial trajectory in 2026 are remarkable. This page compiles the most current statistics on sales, clinical outcomes, market trends, and real-world usage available.

Section 01

What Is Semaglutide — Quick Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is currently approved by the FDA under three brand names, each with distinct indications, dosages, and formulations.

Brand Name	Formulation	FDA Approved For	Dose	Launch Year
Ozempic®	Weekly injection	Type 2 diabetes + cardiovascular risk reduction	0.5mg, 1mg, 2mg weekly	2017
Wegovy®	Weekly injection	Chronic weight management (obesity)	2.4mg weekly	2021
Rybelsus®	Daily oral tablet	Type 2 diabetes	3mg, 7mg, 14mg daily	2019
Wegovy® Pill	Daily oral tablet	Chronic weight management (NEW — Dec 2025)	Up to 25mg daily	Jan 2026

January 2026 milestone: The FDA approved an oral formulation of Wegovy (semaglutide) for chronic weight management in December 2025 — the first GLP-1 pill ever approved for obesity treatment. It launched commercially on January 5, 2026 and became the fastest GLP-1 launch in US history, surpassing 2 million prescriptions in its first four months. (Source: Heally, June 2026)

Section 02

Semaglutide Sales Data 2025–2026

Semaglutide is the best-selling prescription drug franchise in the world by revenue. In 2025 alone, the combined global sales of Ozempic, Wegovy, and Rybelsus exceeded $48 billion — and the 2026 projection is rising further as Wegovy overtakes Ozempic in the US market.

$24.1B

Ozempic global sales 2025 — still the world’s top diabetes drug by revenue

$18.6B

Wegovy global sales 2025 — up 29.2% from 2024

$36B

Total semaglutide franchise projected 2026 global sales

Semaglutide Brand Sales Comparison 2024 vs 2025 (USD Billions)

Source: Novo Nordisk annual filings / IQVIA. Wegovy growing fastest as obesity treatment displaces diabetes focus.

📈

Wegovy Commanding 65% of New US GLP-1 Prescriptions as of May 2026

A major market shift is underway. As of May 2026, Wegovy commands 65% of new US GLP-1 prescriptions — a dramatic shift from just two years ago when Ozempic dominated the weight loss conversation. Wegovy injection sales rose 12% year-over-year in Q1 2026 while Ozempic sales fell 8% in the same period, reflecting the growing physician preference for prescribing the weight-management-specific formulation for obesity treatment. (Source: Heally, June 2026)

💊

Semaglutide Prescription Shift: Obesity Up 8%, Diabetes Down 6.4%

Between March 2025 and June 2025, semaglutide prescriptions for treating diabetes decreased by 6.4% while prescriptions for obesity treatment increased by 8% in the same period. This shift reflects the growing recognition of obesity as the primary indication — and the expansion of insurance coverage for weight management. (Source: SingleCare, June 2026)

Semaglutide Global Revenue Growth 2019–2026 Projected (USD Billions)

Sources: Novo Nordisk financial filings, IQVIA. Revenue has grown more than 15x in 7 years.

Section 03

Semaglutide Clinical Trial Outcomes — STEP Trials

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program is the most comprehensive weight loss trial dataset ever published for a single medication. Here is what all four major STEP trials showed:

Average Weight Loss by STEP Trial — Semaglutide 2.4mg vs Placebo (%)

Sources: NEJM STEP-1 (2021), STEP-2 (2021), STEP-3 (2021), STEP-4 (2021). All at 68 weeks except STEP-4 at 48 weeks.

Trial	Population	Semaglutide	Placebo	Key Finding
STEP-1	Adults with obesity (no T2D)	−15.0%	−2.4%	Most used trial — 68 weeks, 1,961 patients
STEP-2	Adults with obesity + T2D	−9.6%	−3.4%	Lower weight loss in diabetes patients
STEP-3	Adults with obesity + intensive behavioral therapy	−16.0%	−5.7%	Highest loss when combined with lifestyle
STEP-4	Continued vs discontinued treatment	−7.9% more	+6.9% regained	Weight rebounds significantly when stopped
OASIS 4 (Oral)	Adults with obesity — oral Wegovy pill	−16.6%	−2.7%	Oral pill outperforms injectable in trial

Breakthrough finding from OASIS 4: The oral Wegovy pill (25mg semaglutide) achieved 16.6% mean weight loss at 64 weeks with full adherence — outperforming the injectable Wegovy in its primary trial. One-third of adherent participants achieved at least 20% weight loss, versus under 3% with placebo. (Source: Applied Clinical Trials, 2026)

Weight Loss Progress Over Time — STEP-1 Trial

Body Weight Change from Baseline — Semaglutide vs Placebo Over 68 Weeks (STEP-1 %)

Source: Wilding J.P.H. et al., NEJM 2021. Weight loss is progressive and sustained through week 68.

📖 Related at GoalBMI Wellness

Semaglutide Programs — GoalBMI Wellness Semaglutide vs Tirzepatide — Complete Comparison Tirzepatide Side Effects Guide

Section 04

Semaglutide & Cardiovascular Health — SELECT Trial Data

Beyond weight loss, the 2023 SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial established semaglutide as a cardiovascular medication — a landmark finding that expanded its clinical use far beyond obesity treatment.

20%

Reduction in major cardiovascular events (SELECT trial, NEJM 2023)

17,604

Patients enrolled in the SELECT trial — one of the largest cardiovascular trials ever

3.3 yrs

Average trial duration — 39.8 months of follow-up

SELECT Trial Result: A primary cardiovascular end-point event occurred in 6.5% of semaglutide patients versus 8.0% of placebo patients — a hazard ratio of 0.80, representing a statistically significant 20% reduction in major adverse cardiovascular events (MACE). This trial enrolled 17,604 patients with obesity and established cardiovascular disease but without diabetes. (Source: NEJM SELECT Trial, 2023)

SELECT Trial: Cardiovascular Event Rate — Semaglutide vs Placebo (%)

Source: NEJM SELECT Trial, Lincoff et al. 2023. Hazard ratio 0.80 (95% CI: 0.72–0.90; P<0.001).

❤️

Semaglutide Also Reduces Fatty Liver Disease Risk

A 2026 analysis of the SELECT trial found that semaglutide also reduces major heart events and lowers fatty liver disease risk in adults with both obesity and heart disease. Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 4 in 10 American adults and is closely linked to obesity, type 2 diabetes, and high blood pressure. (Source: VCU Health, 2026)

🧠

Semaglutide Linked to Lower Dementia Risk in 1.7 Million Patient Study

A June 2025 study from Case Western Reserve University involving 1.7 million patients found a stunning link between semaglutide use and lower dementia risk. Researchers found that people taking semaglutide showed significantly reduced rates of dementia-related conditions compared to matched controls — suggesting the drug’s benefits may extend to neurological protection. This finding is currently being investigated in dedicated clinical trials. (Source: ScienceDaily, 2025)

👴

Semaglutide Delivers Major Weight Loss in Adults Over 65

A 2026 study presented at the European Association for the Study of Obesity found that older adults (65+) taking once-weekly semaglutide experienced substantial weight loss and improvements in multiple health measures — with results similar to those seen in the broader STEP trial population. This expands the evidenced patient population for semaglutide significantly. (Source: ScienceDaily, May 2026)

Section 05

Who Is Using Semaglutide in America in 2026?

The profile of the typical semaglutide user has shifted dramatically since 2022. What began as a medication primarily prescribed to older adults with type 2 diabetes has evolved into a treatment used predominantly by younger adults for weight management.

Semaglutide User Profile Shift — 2022 vs 2026

Source: Heally.com, June 2026. Based on US prescription data and UK GLP-1 usage comparisons.

32M

US adults who qualify for semaglutide based on weight, diabetes, or CV risk

40%

Non-diabetic weight-loss users now under age 45

77%

Female share of GLP-1 users in comparable UK data

~6%

US adults currently using semaglutide as of mid-2026

Medicare Access Expanding July 1, 2026: Starting July 1, 2026, Medicare Part D will cover weight-loss semaglutide for the first time — bringing an estimated millions of Medicare beneficiaries into the semaglutide market at roughly $50/month copays. This represents the single largest expansion of semaglutide access in US history and is expected to significantly increase prescription volumes in the second half of 2026. (Source: Heally, June 2026)

Key Usage Statistics at a Glance

US adults who qualify for semaglutide (weight/diabetes/CV)32M+

Wegovy share of new US GLP-1 prescriptions (May 2026)65%

Non-diabetic weight-loss users under age 4540%

Wegovy Q1 2026 sales growth YoY+12%

Ozempic Q1 2026 sales change YoY−8%

Section 06

Oral Wegovy — The 2026 Game Changer

The December 2025 FDA approval and January 2026 launch of the Wegovy pill represents one of the most significant events in GLP-1 history — removing the injection barrier that prevented many patients from starting semaglutide treatment.

16.6%

Mean weight loss with oral Wegovy 25mg at 64 weeks — OASIS 4 trial

2M+

Oral Wegovy prescriptions in first 4 months — fastest GLP-1 launch ever

1/3

Of adherent patients achieved 20%+ weight loss with oral Wegovy — OASIS 4

💊

Why the Oral Wegovy Launch Matters for Patients

Fear of needles and the inconvenience of weekly injections are among the most commonly cited barriers to GLP-1 adoption. The oral Wegovy pill removes this barrier entirely — making semaglutide treatment accessible to patients who would never have considered an injectable medication. It started at approximately $149/month for cash-pay patients at launch, making it the most affordable branded semaglutide option in US history.

📍 Semaglutide Programs at GoalBMI Wellness

Semaglutide New York Semaglutide New Jersey Semaglutide Pennsylvania Program Pricing & Insurance

Real Patient Outcomes

Before & After — Semaglutide & Tirzepatide Results at GoalBMI Wellness

These outcomes reflect real patients from physician-supervised GLP-1 programs at GoalBMI Wellness — including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) programs. Results are consistent with what the STEP and SURMOUNT trials showed under supervised conditions.

Before and after weight loss results from semaglutide and tirzepatide programs — GoalBMI Wellness physician-supervised telehealth

Results disclaimer: Individual results may vary. Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent. Results depend on individual health factors, program adherence, and clinical evaluation. All medications require a licensed provider evaluation and prescription.

Clinical context: STEP-1 showed semaglutide produced 15% average body weight loss at 68 weeks. SURMOUNT-1 showed tirzepatide produced 20–22.5% average weight loss at 72 weeks. Both results are significantly greater than any previously available non-surgical weight loss intervention. GoalBMI Wellness telehealth programs are built around the same clinical protocols used in these trials — with physician supervision delivered entirely online.

Semaglutide Programs → Tirzepatide Programs →

Transparent Pricing

Semaglutide Program Pricing at GoalBMI Wellness

Understanding what semaglutide costs — and what your options are — is essential before starting treatment. GoalBMI Wellness offers transparent self-pay pricing and insurance verification assistance for eligible patients.

GoalBMI Wellness semaglutide and tirzepatide telehealth program pricing — self-pay and insurance options

💰

2026 Semaglutide Pricing Context

In November 2025, the Trump administration announced a negotiated price agreement capping Wegovy and Ozempic at $245 per month through TrumpRx — less than half of prior market prices. The new oral Wegovy pill launched at approximately $149/month for cash-pay patients. GoalBMI Wellness also works with licensed 503A compounding pharmacies to provide cost-effective options when clinically appropriate. Medicare Part D begins covering weight-loss semaglutide from July 1, 2026 at roughly $50/month copays. See our program pricing page for current options.

View Program Pricing → Verify Insurance →

Section 07

Semaglutide Timeline — Key Milestones

2017

Ozempic FDA Approved for Type 2 Diabetes

Novo Nordisk’s weekly injectable semaglutide (Ozempic) receives FDA approval for type 2 diabetes management. The SUSTAIN trials had demonstrated significant HbA1c reductions and a cardiovascular benefit signal — setting the stage for broader GLP-1 development.

2019

Rybelsus — First Oral GLP-1 for Diabetes Approved

FDA approves Rybelsus, the first oral semaglutide tablet for type 2 diabetes management — proving that the GLP-1 mechanism could be effective in pill form and setting up the later oral Wegovy development.

June 2021

Wegovy FDA Approved — Weight Loss Era Begins

Wegovy (semaglutide 2.4mg) becomes the first major GLP-1 approval specifically for chronic weight management in adults with obesity. The landmark STEP-1 trial showed 15% average weight loss — unprecedented for a non-surgical treatment. TikTok and celebrity endorsements trigger a cultural phenomenon around “Ozempic for weight loss.”

2022–2023

Ozempic Shortage — Global Supply Crisis

The explosion in off-label Ozempic prescriptions for weight loss depletes global supply, creating a shortage that makes global news. The shortage ironically introduces even more people to semaglutide by raising awareness. Novo Nordisk accelerates manufacturing expansion.

August 2023

SELECT Trial Published — Cardiovascular Breakthrough

The NEJM publishes the SELECT trial results — 17,604 patients, 20% reduction in major cardiovascular events. Semaglutide is no longer just a weight loss drug; it is now an evidence-based cardiovascular treatment. This triggers a new wave of prescribing and insurance coverage expansion.

January 2025

FDA Approves Ozempic for Kidney Disease Reduction

FDA approves Ozempic for a new indication: reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Semaglutide’s clinical indications now span diabetes, obesity, cardiovascular disease, and kidney disease.

December 2025

Oral Wegovy Approved — First GLP-1 Pill for Obesity

FDA approves oral semaglutide (Wegovy pill) for chronic weight management — the first GLP-1 pill ever approved for obesity treatment. The OASIS 4 trial showed 16.6% mean weight loss with full adherence — outperforming the injectable trial results. The pill launches January 5, 2026 at approximately $149/month for cash-pay patients.

2026

Oral Wegovy Breaks Records — Medicare Coverage Begins July 1

The oral Wegovy pill surpasses 2 million prescriptions in its first four months — the fastest GLP-1 launch in history. Wegovy commands 65% of new US GLP-1 prescriptions. Medicare Part D begins covering weight-loss semaglutide from July 1, 2026. Total semaglutide franchise projected at $36 billion for the year. Semaglutide is now studied for dementia prevention, fatty liver disease, and addiction treatment.

Section 08

Frequently Asked Questions

Ozempic and Wegovy contain the same active ingredient — semaglutide — but are approved for different indications at different doses. Ozempic (0.5mg, 1mg, 2mg weekly) is FDA-approved for type 2 diabetes management and cardiovascular risk reduction. Wegovy (2.4mg weekly) is FDA-approved specifically for chronic weight management in adults with obesity or weight-related health conditions. The higher dose in Wegovy produces greater weight loss outcomes.

According to the STEP-1 clinical trial, patients using semaglutide 2.4mg (Wegovy) lost an average of 15% of body weight over 68 weeks — compared to 2.4% in the placebo group. When combined with intensive behavioral therapy (STEP-3), average weight loss reached 16%. The new oral Wegovy pill (OASIS 4 trial) showed 16.6% average weight loss at 64 weeks with full adherence. Individual results vary based on dose, adherence, diet, physical activity, and health history.

The oral Wegovy pill is a daily tablet formulation of semaglutide approved by the FDA in December 2025 for chronic weight management — the first GLP-1 pill ever approved for obesity treatment. It works through the same mechanism as injectable semaglutide but is taken orally, eliminating the need for injections. In the OASIS 4 trial, the 25mg daily pill achieved 16.6% mean weight loss at 64 weeks with full adherence. It launched in the US on January 5, 2026, starting at approximately $149/month for cash-pay patients.

Yes. The landmark SELECT trial, published in the NEJM in 2023, demonstrated that semaglutide reduces major adverse cardiovascular events (MACE) by 20% in adults with obesity and established cardiovascular disease. The trial enrolled 17,604 patients and ran for nearly 4 years. This result led to FDA approval of Wegovy for an additional cardiovascular indication in March 2024. A 2026 analysis of SELECT data also found semaglutide reduces fatty liver disease risk.

Following the TrumpRx pricing agreement in November 2025, brand-name Wegovy and Ozempic are available at $245 per month through this program. The new oral Wegovy pill started at approximately $149/month for cash-pay patients. Medicare Part D begins covering weight-loss semaglutide from July 1, 2026 at roughly $50/month copays. Compounded semaglutide may be available at lower costs through licensed 503A pharmacies when appropriate. GoalBMI Wellness offers insurance verification to help check your coverage. Visit our pricing page for current program costs.

Yes. GoalBMI Wellness provides physician-supervised semaglutide programs for eligible patients in New York, New Jersey, Pennsylvania, and Connecticut through our telehealth platform. When clinically appropriate, providers may prescribe semaglutide as Wegovy® or Ozempic®. Compounded semaglutide may also be available through licensed 503A pharmacies. All consultations, prescriptions, and follow-up care are conducted entirely online — no in-person office visits required. Visit wellness.goalbmi.com/contacts/ to get started.

References

Sources & Medical References

1Wilding J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). NEJM, 384(11), 989–1002. doi.org/10.1056/NEJMoa2032183
2Lincoff A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 389, 2221–2232. doi.org/10.1056/NEJMoa2307563
3Applied Clinical Trials (2026). FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results. appliedclinicaltrialsonline.com
4Heally.com (June 17, 2026). Semaglutide in 2026: Usage Statistics, Top Brands, and Market Trends. getheally.com
5SingleCare (June 2026). Ozempic Statistics 2026 — Usage, Prescriptions and Market Data. singlecare.com
6VCU Health (2026). Semaglutide reduces major heart events and lowers fatty liver disease risk in adults with obesity. vcuhealth.org
7ScienceDaily (May 2026). Ozempic delivers major weight loss in adults over 65, study finds. European Association for the Study of Obesity. sciencedaily.com
8Nature npj Cardiovascular Health (July 2026). Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss. 505,874 patient analysis. nature.com
9NIH / NCBI StatPearls (2024). Semaglutide — pharmacology, indications, and clinical considerations. ncbi.nlm.nih.gov
10U.S. Food and Drug Administration (2023). Wegovy (semaglutide) prescribing information. accessdata.fda.gov
11Novo Nordisk Annual Report (2025). Financial results for semaglutide brands — Ozempic, Wegovy, Rybelsus. novonordisk.com
12PMC / NCBI (2025). Semaglutide for cardiovascular risk reduction in people with overweight or obesity without diabetes. pmc.ncbi.nlm.nih.gov
13ScienceDaily (June 2025). 1.7 Million Patients Reveal Stunning Link Between Semaglutide and Lower Dementia Risk. Case Western Reserve University. sciencedaily.com

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, peptide therapy, and telehealth wellness care through GoalBMI Wellness. All statistical data in this article was reviewed for clinical accuracy in July 2026.

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Statistics are sourced from peer-reviewed studies, government agencies, and authoritative research organizations as cited. GoalBMI Wellness provides physician-supervised telehealth programs for eligible patients in participating states. In a medical emergency, call 911.

Get Started

Book an appointment and take the first step toward better health.

Book Now

Related Weight Loss Programs